EVH trade ideas
$EVH*For share traders only. Not meant for options.
Green: Entry Point
Blue: Start of Week
Red: End of Week
Thumbs Up: Trade Available for Week
$ Amount (Numbers Above): Price Targets
*I don’t believe in sharing strategies or outlooks due to the idea that it could cause someone confusion within. It’s important in trading to find your eyes and do things that match your scope of understanding. Over time, if the work is put in, you will create a strategy that in most cases aren’t full proof, but something you can lean on creating an edge for yourself. This strategy is based on a mix of volume analysis, Elliot Waves, retracements, and candlestick anomalies.
EVH, 5/14-5/29, -9.5% LOSSOn 5/9/2024, Evolent Health (EVH) reported earnings of $0.16 per share on revenue of $639.65 million for the first quarter ended March 2024. The consensus earnings estimate was $0.12 per share on revenue of $601.60 million. The company beat consensus estimates by 33.33% while revenue grew 49.56% on a year-over-year basis.
EVH (Evolent Health) Buy TF H4 TP = 30.08On the 4-hour chart the trend started on August 29 (linear regression channel).
There is a high probability of profit taking. Possible take profit level is 30.08
But we should not forget about SL = 24.64
Using a trailing stop is also a good idea!
Please leave your feedback, your opinion. I am very interested in it. Thank you!
Good luck!
Regards, WeBelieveInTrading
EVH (Evolent Health, Inc. ) Buy TF H1 TP = 30.65On the hour chart the trend started on August 7 (linear regression channel).
There is a high probability of profit taking. Possible take profit level is 30.65
But we should not forget about SL = 27.71
Using a trailing stop is also a good idea!
Please leave your feedback, your opinion. I am very interested in it. Thank you!
Good luck!
Regards, WeBelieveInTrading
sell EVH short1. ER disaster & Bounce and roll structure
2. break volume POC
3. MA congestion
4. Lower high and reversal at high. Cannot break 50MA
Also note the negative vol profile
Fundamental peaked. Next year earning negative and decreasing but PE still high, may need to catch up to the downside.
This could be an example of price leading the fundamental, where the fundamental still looks good, e.g. earning/sales/margin all accelerating expansion, and notable funds were still adding. However, a hint is the total fund count has peaked.
Descending Triangle Price is below support line.
Oversold.
Price remains above the .382 of the trend up.
Earning's date conflicts, but is early November.
No recommendation.
EPS (FWD)
0.40
PE (FWD)
75.93
Div Rate (TTM)
Short Interest
7.88%
Market Cap
$2.95B
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
EVH - new 52 week high. Breaking out and holdingBreaking out of one month consolidation. Constructive price and volume action and a market leader.
You don't need to know what's going to happen next to make money ~Mark Douglas
Lose like a pro and keep trading, or lose like a novice and quit ~Mark Ritchie
$EVH Merger with Walgreens Will Not Happen Sources SayWe all come here to notice that Walgreens is not interested in the Merger with EVH after digging into the company earnings and realizing there's a conflict of interest in proprietary technology. A Merger makes no sense any more spokesman said. "We'd like to notify private investors today to let them know that the deal doesn't seem to fit our model anymore as far as the health care management software Evolent has to offer" - Walgreens
WACC% 15.48
ROIC -3.73
Operating Margin -4.18
Net Margin -7.28
ROE -11.23
ROA -5.35
3 Year EPS NRI Growth Rate -61.20
Net Income Operations -72.27 70% Worse than 606 companies
Sloan Ratio -42.26
ROCE -4.49
1 Year Asset Growth Rate -7.30
1 Year Debt Growth Rate -21.80
1 Year OCF -881
1 Year Total Growth Rate 8.80
1 Year Revenue Rate Per Share 5.70
EVh Price Target $25 by October 15th 2021 BEAR TREND INDICATORWAC 15% HIGH EVolve ROIC -4% . Many people are speaking about a merger, this suggestion is a misnomer as why would a bullish running company catored to the Software industry be under merger talks? With who?
WACC% 15.48 ROIC -3.73 Operating Margin -4.18 Net Margin -7.28 ROE -11.23 ROA -5.35 3 Year EPS NRI Growth Rate -61.20 Net Income Operations -72.27 70% Worse than 606 companies Sloan Ratio -42.26 ROCE -4.49 1 Year Asset Growth Rate -7.30 1 Year Debt Growth Rate -21.80 1 Year OCF -881 1 Year Total Growth Rate 8.80 1 Year Revenue Rate Per Share 5.70
70 Worse than 606 companies in Health Care
High WACC 15%+
Worst ROIC -4%
Evolent Health Inc Cl A Com (EVH)Evolent Health Inc Cl A Com (EVH)
WBA is in talks with Evolent to buy its healthcare industry peer. Citing "people familiar with the matter," Bloomberg pointed out that Evolent is experiencing pressure from activist investor Engaged Capital to consider a sale, among other "value creation" measures.
The target price could be $35.20
GoodLuck
insiders buying and agreement with Molina ?!I feel like the company is planning something big and quick. They have extended their contract with Molina and that can only mean more money. think this will dip to 8 which would be a great buying opportunity. I do believe the stock has potential to rise to 10.70 in the future.